Stay updated on INTEGA: Ipilimumab & FOLFOX + Nivolumab & Trastuzumab Clinical Trial
Sign up to get notified when there's something new on the INTEGA: Ipilimumab & FOLFOX + Nivolumab & Trastuzumab Clinical Trial page.

Latest updates to the INTEGA: Ipilimumab & FOLFOX + Nivolumab & Trastuzumab Clinical Trial page
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedMinor UI text and label changes were made, including the addition of glossary toggle options and small wording/case updates (e.g., 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0'). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check22 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed; this update does not change the study content, eligibility criteria, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check51 days agoChange DetectedFooter now includes Revision: v3.3.3; the HHS Vulnerability Disclosure and Revision: v3.3.2 items were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check73 days agoChange DetectedPublications description updated to 'These publications are automatically filled in from PubMed, a public database of scientific and medical articles, and may or may not be about the study,' and the page revision label changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check80 days agoChange DetectedAdministrative funding status notice was removed from the page. The rest of the study details, eligibility criteria, and intervention descriptions remain unchanged.SummaryDifference0.3%

- Check102 days agoChange DetectedThe new screenshot shows minor formatting and wording adjustments across the page; core trial details, arms, outcomes, and listed locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to INTEGA: Ipilimumab & FOLFOX + Nivolumab & Trastuzumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INTEGA: Ipilimumab & FOLFOX + Nivolumab & Trastuzumab Clinical Trial page.